Health2Sync Secures $20M in Series C Funding to Accelerate Digital Therapeutics for Diabetes Care

Health2Sync is thrilled to announce that we have successfully raised $20,000,000 in our latest funding round—a monumental milestone that reinforces our commitment to revolutionizing health management for individuals with diabetes and beyond.

Founded in June 2013, Health2Sync has consistently been at the forefront of innovative patient care by providing a comprehensive health management platform that connects patients with family, friends, and care providers.

Our flagship mobile app, a trusted companion for managing diabetes, enables users to effortlessly track blood sugar levels and understand the myriad factors that influence their health.

Recognized by Healthline as one of the "10 Best Diabetes Apps" for three consecutive years since 2017 and now serving over 1.

2 million users worldwide, Health2Sync has built an extraordinary reputation for blending mobile, cloud, and data analysis technologies to enhance patient care quality.

The recent infusion of capital will play a pivotal role in accelerating the development of our first digital therapeutic product, designed to empower patients with more efficient tools for self-management of blood glucose levels.

This next-generation solution is poised to transform traditional diabetes management by integrating evidence-based practices with cutting-edge digital innovation.

As we harness these funds to scale our platform further, invest in robust research and development, and expand our reach to new markets, our mission remains clear: to deliver innovative, convenient, and effective healthcare solutions that improve lives around the globe.

We look forward to embarking on this exciting next chapter and remain committed to enhancing the way patients interface with their health every step of the way.